All Liraglutide (Saxenda) articles

News

Teva wins US obesity approval for its GLP-1 generic liraglutide

2025-08-29T13:23:58Z

And Eli Lilly and Company’s new oral GLP-1 obesity therapy orforglipron shines in late-phase clinical trials.